Introduced in House — H.R. 8630

119th CONGRESS

2d Session

H. R. 8630

IN THE HOUSE OF REPRESENTATIVES

April 30, 2026

Mr. Rulli (for himself and Mrs. Harshbarger) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.

Section 1. Short title

This Act may be cited as the Protecting Equal Access to Thyroid Act of 2026 or the PEAT Act of 2026.

Sec. 2. Prohibition with respect to treatment of proteins in biologics

(a) In general

Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended—

(1)

by striking The term and inserting the following:

(A)
The term; and

(2)

by adding at the end the following:

(B)
A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.

(b) Technical correction

Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking protein , and inserting protein,.